Inside Precision Medicine May 22, 2024
Chris Anderson

The results of two back-to-back randomized double-blind placebo controlled trials has shown that a 100-year-old vaccine originally developed to prevent tuberculosis helps protect people with type 1 diabetes from COVID-19 and other infectious diseases. The research by investigators at the Massachusetts General Hospital (MGH) found that the Bacillus Calmette-Guérin (BCG) vaccine provided continuous protection against all the viral variants for almost the entire COVID-19 pandemic.

The results of the 18-month trial are published today in iScience. The Phase III trial was conducted later in the pandemic when the Omicron variant was circulating in the population. An earlier Phase II trial was conducted earlier in the pandemic, and those results were published in the journal Cell Reports Medicine.

“Individuals with type...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Federal Support Should Not Be A Factor In Determining Pharmaceutical Prices Under The IRA
FDA to vaccinemakers: Updated COVID shots should target KP.2 variant
Mark Cuban: Pharma has been 'easiest industry' to disrupt
Charlie Swanton: A Master Class on Cancer
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial

Share This Article